(Q46484861)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

Talerngsak Kanjanabuch

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

O Traitanon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Y Avihingsanon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

V Kittikovit

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

N Townamchai

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

K Praditpornsilpa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

J Wongchinasri

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

K Tungsanga

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

S Eiam-Ong

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 August 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

744-751

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625653%20AND%20SRC:MED&resulttype=core&format=json

"Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis.

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Therapeutic options for resistant lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

The safety and efficacy of MMF in lupus nephritis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Mycophenolate mofetil in lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Lupus nephritis: treatment with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Silent nephritis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090991